

Quantity Limit Criteria

Short Acting Beta2-Adrenergic Agonist, Combination Oral Inhalation

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Airsupra	albuterol and budesonide inhalation aerosol
albuterol inhalation solution (brand unavailable)	albuterol inhalation solution
albuterol sulfate HFA (brand unavailable)	albuterol
Proair Digihaler	albuterol
Proair Respiclick	albuterol
Proventil HFA	albuterol
Ventolin HFA	albuterol
Xopenex Solution	levalbuterol
Xopenex Concentrate	levalbuterol
Xopenex HFA	levalbuterol

Indications

FDA-approved Indications

Airsupra

Airsupra is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older.

Albuterol sulfate HFA (generic for ProAir HFA)

Bronchospasm

Albuterol Sulfate HFA Inhalation Aerosol is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Albuterol Sulfate HFA Inhalation Aerosol is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Albuterol Sulfate Inhalation Solution 0.63 mg/3 mL and 1.25 mg/3 mL

Albuterol Sulfate Inhalation Solution is indicated for the relief of bronchospasm in patients 2 to 12 years of age with asthma (reversible obstructive airway disease).

Albuterol Sulfate Inhalation Solution 0.083% (2.5 mg/3 mL)

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

Albuterol Sulfate Inhalation Solution 0.5% (2.5 mg/0.5 mL)

0.5 mL Vial

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

20 mL Bottle

Albuterol sulfate inhalation solution is indicated for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.

ProAir Digihaler

Bronchospasm

ProAir Digihaler is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

ProAir Digihaler is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

ProAir Respiclick

Bronchospasm

ProAir Respiclick is indicated for the treatment or prevention of bronchospasm in patients 4 years of age and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

ProAir Respiclick is indicated for the prevention of exercise-induced bronchospasm in patients 4 years of age and older.

Proventil HFA

Proventil HFA Inhalation Aerosol is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.

Ventolin HFA

Bronchospasm

Ventolin HFA is indicated for the treatment or prevention of bronchospasm in adult and pediatric patients aged 4 years and older with reversible obstructive airway disease.

Exercise-Induced Bronchospasm

Ventolin HFA is indicated for the prevention of exercise-induced bronchospasm in adult and pediatric patients aged 4 years and older.

Xopenex Solution

Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xopenex Concentrate

Xopenex (levalbuterol HCl) Inhalation Solution Concentrate is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease.

Xopenex HFA

Xopenex HFA is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 4 years of age and older with reversible obstructive airway disease.

Initial Limit Criteria

Limits do not accumulate together; patient is allowed the maximum limit for each drug and strength.

PLEASE NOTE: Since manufacturer package sizes may vary, it is the discretion of the dispensing pharmacy to fill quantities per package size up to these quantity limits. In such cases the filling limit and day supply may be less than what is indicated.

The duration of 25 days is used for a 30-day fill period and 75 days is used for a 90-day fill period to allow time for refill processing.

Medication	Maintenance Dose	Maximum Daily Dose	Package Size	1 Month Limit 3 Month Limit
Airsupra (albuterol and budesonide)	2 inhalations as needed	12 inhalations	120 inhalations per 10.7 gm canister	3 packages (10.7 gm each) / 25 days 9 packages (10.7 gm each) / 75 days
Albuterol 0.63 mg/3 mL, 1.25 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	25 vials (3 mL each) per carton	5 packages (125 vials x 3 mL) / 25 days 15 packages (375 vials x 3 mL) / 75 days
Albuterol 0.63 mg/3 mL, 1.25 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	30 vials (3 mL each) per carton	4 packages (120 vials x 3 mL) / 25 days 12 packages (360 vials x 3 mL) / 75 days
Albuterol 0.083%, 2.5 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	25 vials (3 mL each) per carton	5 packages (125 vials x 3 mL) / 25 days 15 packages (375 vials x 3 mL) / 75 days
Albuterol 0.083%, 2.5 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	30 vials (3 mL each) per carton	4 packages (120 vials x 3 mL) / 25 days 12 packages (360 vials x 3 mL) / 75 days
Albuterol 0.083%, 2.5 mg/3 mL Inhalation Solution	nebulization of 1 vial (3 mL) three to four times daily	4 vials (3 mL each)	60 vials (3 mL each) per carton	2 packages (120 vials x 3 mL) / 25 days 6 packages (360 vials x 3 mL) / 75 days
Albuterol 0.5%, 2.5 mg/0.5 mL Inhalation Solution	nebulization of 0.25 mL-0.5 mL three to four times daily	2 mL	20 mL per bottle	3 packages (20 mL each) / 25 days 9 packages (20 mL each) / 75 days
Albuterol 0.5%, 2.5 mg/0.5 mL Inhalation Solution	nebulization of 0.25 mL-0.5 mL three to four times daily	2 mL	30 vials (0.5 mL each) per carton	4 packages (120 vials x 0.5 mL) / 25 days 12 packages (360 vials x 0.5 mL) / 75 days
Albuterol sulfate HFA	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 8.5 gm canister	2 packages (8.5 gm each) / 25 days 6 packages (8.5 gm each) / 75 days
ProAir Digihaler (albuterol)	1-2 inhalations	12 inhalations	200 inhalations per inhaler	2 packages / 25 days 6 packages / 75 days

Medication	Maintenance Dose	Maximum Daily Dose	Package Size	1 Month Limit 3 Month Limit
	every 4 to 6 hours			
ProAir RespiClick (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per inhaler	2 packages / 25 days 6 packages / 75 days
Proventil HFA (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 6.7 gm canister	2 packages (6.7 gm each) / 25 days 6 packages (6.7 gm each) / 75 days
Ventolin HFA (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	60 inhalations per 8 gm canister	6 packages (8 gm each) / 25 days 18 packages (8 gm each) / 75 days
Ventolin HFA (albuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 18 gm canister	2 packages (18 gm each) / 25 days 6 packages (18 gm each) / 75 days
Xopenex 0.31 mg, 0.63 mg, 1.25 mg/3 mL (levalbuterol)	nebulization of 1 vial (3 mL) three times daily	3 vials (3 mL each)	24 vials (3 mL each) per carton	4 packages (96 vials x 3mL) / 25 days 12 packages (288 vials x 3 mL) / 75 days
Xopenex 0.31 mg, 0.63 mg, 1.25 mg/3 mL (levalbuterol)	nebulization of 1 vial (3 mL) three times daily	3 vials (3 mL each)	25 vials (3 mL each) per carton	4 packages (100 vials x 3 mL) / 25 days 12 packages (300 vials x 3 mL) / 75 days
Xopenex 0.31 mg, 0.63 mg, 1.25 mg/3 mL (levalbuterol)	nebulization of 1 vial (3 mL) three times daily	3 vials (3 mL each)	30 vials (3 mL each) per carton	3 packages (90 vials x 3 mL) / 25 days 9 packages (270 vials x 3 mL) / 75 days
Xopenex Concentrate 1.25 mg/0.5 mL (levalbuterol)	nebulization of 1 vial (0.5 mL) three times daily	3 vials (0.5 mL each)	30 vials (0.5 mL each) per carton	3 packages (90 vials x 0.5 mL) / 25 days 9 packages (270 vials x 0.5 mL) / 75 days
Xopenex HFA (levalbuterol)	1-2 inhalations every 4 to 6 hours	12 inhalations	200 inhalations per 15 gm canister	2 packages (15 gm each) / 25 days 6 packages (15 gm each) / 75 days

References

1. Airsupra [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; March 2024.
2. Albuterol sulfate HFA [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; January 2023.
3. Albuterol sulfate inhalation solution 0.63 mg/3 mL and 1.25 mg/3 mL [package insert]. Columbia, SC: Ritedose Pharmaceuticals, LLC; May 2022.
4. Albuterol sulfate inhalation solution 0.083% [package insert]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; December 2023.
5. Albuterol sulfate inhalation solution, 0.5% (0.5 mL) [package insert]. West Columbia, SC: Nephron Pharmaceuticals Corporation; January 2021.
6. Albuterol sulfate inhalation solution, 0.5% (20 mL) [package insert]. Amityville, NY: Hi-Tech Pharmacal Co., Inc.; February 2017.
7. Levalbuterol inhalation solution [package insert]. Memphis, TN: NorthStar Rx LLC; February 2023.
8. Levalbuterol solution, concentrate [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; October 2022.
9. ProAir Digihaler [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; December 2022.
10. ProAir Respiclick [package insert]. Parsippany, NJ: Teva Pharmaceuticals USA, Inc.; September 2022.
11. Proventil HFA [package insert]. Princeton, NJ: Sandoz Inc.; December 2020.
12. Ventolin HFA [package insert]. Research Triangle Park, NC: GlaxoSmithKline; April 2024.
13. Xopenex inhalation solution [package insert]. Lake Forest, IL: Akorn, Inc.; December 2018.
14. Xopenex inhalation solution concentrate [package insert]. Lake Forest, IL: Akorn, Inc.; December 2018.
15. Xopenex HFA [package insert]. Baltimore, MD: Lupin Pharmaceuticals Inc.; November 2023.

Document History

Written by: UM Development (KB)

Date Written: 06/2002

Reviewed: (MG) 06/2003, 11/2004, 03/2005 (Xopenex HFA and Albuterol HFA added); (NB) 03/2006, 09/2006 (Advair HFA added); (CT) 03/2007(2) (Perforomist added), 02/2008, 02/2009, 09/2009 (updated Xopenex soln limit 02/2009(2)); (MS) 01/2010; (RP) 02/2011, 07/2011 (Arcapta Neohaler added), 06/2012; (TM) 02/2013, 05/2013 (add Breo Ellipta), 11/2013 (separate short and long acting), 11/2014, 04/2015; (MS) 11/2015 (no clinical changes); (TM) 11/2016 (no clinical changes), 11/2017 (no clinical changes), 11/2018 (no clinical changes), 12/2018 (add ProAir Digihaler), 11/2019 (no clinical changes), 11/2020 (no clinical changes); (RZ) 09/2021 (no clinical changes); (KMB) 10/2022 (no clinical changes); (VLS) 01/2023 (added Airsupra); (MRS) 09/2023 (no clinical changes); (NSS) 08/2024 (removed brand ProAir HFA)

Reviewed: CRC 06/2003; CDPR/Medical Affairs (MM) 11/2004, 03/2005, 03/2006; (WF) 03/2007(2), 02/2008, 02/2009, 09/2009, 02/2010; (KP) 02/2011; (KP) 07/2011, 06/2012, (LS) 02/2013, (LB) 05/2013, (DC) 11/2013, (DNC) 11/2014, (SES) 04/2015, (AM) 01/2019, (CHART) 11/27/19, 12/03/2020, 09/30/2021, 09/22/2022, 09/28/2023, 08/29/2024

Reference number(s)
1086-H

External Review: 08/2003, 12/2004, 11/2005, 06/2006, 06/2007, 06/2008, 06/2009, 06/2011, 10/2011, 10/2012, 06/2013, 01/2014, 02/2015, 02/2016, 02/2017, 02/2018, 02/2019 (FYI), 02/2019, 02/2020, 02/2021, 02/2022, 02/2023, 02/2024, 12/2024